ERBB2 and breast carcinoma: The HR-positive breast carcinoma sufferers with moderate HER2-expressing HER2 2+ have been reported to exhibit inferior DFS to those with HER2 1+ or 0 but no difference in BCSS (breast carcinoma-specific survival: duration between the operative date and the date of final follow-up or breast carcinoma-induced death) (20).